Onkológia 6/2016

Current position of vinorelbine within complex breast cancer treatment

Vinorelbine is active cytostatic agent used in treatment of advanced breast cancer. There are only few phase III studies evaluating its efficacy and safety. It is most commonly used in anthracycline and taxane pretreated patients. In addition to venous administration it is also available in oral form with high bioavailability. Vinorelbine can be administered alone or in combination therapy with capecitabine or gemcitabine, in this cases higher response rate and higher toxicity is expected. Therefore vinorelbine combination therapy is reserved for patients with aggressive disease. It has an irreplaceable role in the treatment of HER2 positive breast cancer, with possible combination with trastuzumab, pertuzumab and lapatinib.

Keywords: vinorelbine, breast cancer, metastatic, per oral, intravenous